Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation
Authors:
- J ShepherdJSJ Shepherd
- H BrodinHBH Brodin
- C CaveCCC Cave
- N WaughNWN Waugh
- A PriceAPA Price
- J GabbayJGJ Gabbay
Open Access
- 1 October 2004
- journal article
- review article
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 8 (39)
Abstract
Health Technology Assessment Volume: 8, Issue: 39, Published in October 2004Keywords
Funding Information
- Health Technology Assessment Programme (02/20/01)
This publication has 75 references indexed in Scilit:
- Ribavirin with or without alpha interferon for chronic hepatitis CCochrane Database of Systematic Reviews, 2002
- Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis CHepatology, 1999
- Health-related quality of life in chronic hepatitis C: Impact of disease and treatment responseHepatology, 1999
- The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1aJournal of Medical Virology, 1999
- Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trialHepatology, 1998
- Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology, 1998
- Hepatitis C: The clinical spectrum of diseaseHepatology, 1997
- Hepatitis C in asymptomatic blood donorsHepatology, 1997
- Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisalHepatology, 1995
- A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis CGastroenterology, 1994